W. O. Siegl, M. Zinbo, T. J. Korniski, J. F. O. Richert, E. Chladek, M. C. Paputa Peck, J. E. Weir, D. Schuetzle and T. E. Jensen A study was carried out to increase ...
Radiation Research, Vol. 152, No. 6, Supplement: The International Workshop on the Health Effects of Thorotrast, Radium, Radon and Other Alpha-Emitters 1999 (Dec., 1999), pp. S43-S47 (5 pages) There ...
Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to ...
LONDON, UK, 4 March 2025 - In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumours (NETs), a ...
Perspective Therapeutics' pipeline, led by VMT-a-NET, shows promising safety and early efficacy, but lacks clear superiority over existing therapies like Lutathera so far. The company maintains a ...
Drs. Kalyan M. Shekhda1 (Royal Free Hospital, London, UK), Shaunak Navalkissoor Royal Free Hospital, London, UK), and Ashley B. Grossman (University of Oxford and Queen Mary University of London, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback